Hormone therapy succeeds or fails on the strength of its goals. Numbers guide us, but symptoms, safety, and life stage shape the destination. I have seen people feel flat despite “normal” lab values, and others thrive with results that sit at the edges of a reference interval. The art is knowing when to respect the range and when to personalize within it, then to keep watching as bodies, goals, and risks evolve.
This guide lays out typical target ranges, how I set personalized objectives, and where different delivery methods fit. It also covers the hard parts: assay quirks, timing of tests, the uncomfortable trade-offs behind terms like “bioidentical,” and the places where chasing a number can do more harm than good.
Reference ranges versus personal targets
Reference ranges are not optimal ranges. They reflect the central 95 percent of values seen in a defined population using a specific assay. That population may include people with undiagnosed disease, smokers, those on medications, and wide age variation. A 33-year-old athlete and a 68-year-old with metabolic syndrome can both sit within the same “normal” band while feeling very different.
Personal targets sit inside or near those ranges, with the goal of consistent symptom relief, objective improvement in function, and acceptable risk. For example, I often aim for mid to upper normal free testosterone in a symptomatic 48-year-old man after ruling out sleep apnea and thyroid issues, while I may aim lower for a 72-year-old with prior erythrocytosis. A perimenopausal woman with hot flashes and migraines may do better on lower serum estradiol delivered transdermally, prioritizing stability and safety over a specific absolute number.
How laboratories and timing can mislead
Two labs can give two different answers from the same blood draw. Estradiol assays perform poorly at low levels, especially in men and in postmenopausal women. Testosterone immunoassays can misread in women due to cross-reactivity, which is why LC-MS/MS methods matter when levels are low.
Timing matters. Testosterone peaks after an injection and dips before the next dose. Oral estrogen raises clotting factors disproportionate to measured serum estradiol. Thyroid stimulating hormone drifts across the day and adapts slowly over weeks to a dose change. If you draw labs at the wrong time, you might fix the wrong problem.
I standardize blood draws where possible: morning sampling for cortisol, TSH at least six weeks after dose changes, testosterone levels midway between injections or as troughs depending on the regimen, and estradiol checks for transgender care at consistent intervals after dose stabilization.
Building a personal goal: the four-part framework
When I set targets, I use four inputs: symptoms, objective data, risk profile, and practical preferences. A middle-aged man with low libido, depressed mood, and low total testosterone on two morning tests is not the same as a new father with identical labs and severe sleep loss. A woman eight years past her final period with severe night sweats and osteopenia has different stakes than a perimenopausal lawyer with episodic migraines and family history of breast cancer. The personal history recasts the same numbers into different decisions.
Risk tolerance matters too. If a patient wants pellet hormone therapy for convenience but has a tendency for high hematocrit, I advise against pellets because reversal is slow and peaks can be high. If a patient values plant-sourced bioidentical hormone therapy but travels often, a transdermal patch can provide consistent delivery with lower clot risk than oral estrogen.
Key hormones, typical target ranges, and how I adjust
Even with personalization, it helps to have landmarks. The ranges below are commonly used targets or reference intervals in adults, with context for nuance. Units vary by lab; I use typical United States units and note when levels are age dependent.
Testosterone
- Men: Most labs report a reference range around 300 to 1,000 ng/dL for total testosterone. For symptomatic men on testosterone replacement therapy, I usually aim for mid-normal values, commonly 400 to 700 ng/dL as a trough for weekly injections, or 500 to 800 ng/dL measured midway for a twice-weekly plan. Free testosterone goals depend on sex hormone binding globulin. I watch symptoms and aim for free testosterone in the mid to upper half of the lab’s reference interval without pushing hematocrit above 54 percent. Women: Total testosterone in premenopausal women often ranges roughly 15 to 70 ng/dL. I use sensitive LC-MS/MS assays. For low libido and fatigue associated with low testosterone, careful low-dose therapy may target restoring levels to the premenopausal range, keeping an eye on acne, hair growth, and voice changes. I avoid supraphysiologic peaks and consider discontinuation if side effects appear despite dose reduction.
Estradiol and progesterone in women
- Estradiol: In natural cycles, estradiol ranges widely, from around 30 to 120 pg/mL in the early follicular phase to 130 to 370 pg/mL at midcycle, then 70 to 250 pg/mL in the luteal phase. After menopause, levels commonly fall below 20 pg/mL. For menopause hormone therapy, symptom relief, sleep quality, and bone protection matter more than a single serum value. Transdermal estrogen often provides relief when levels reach roughly 50 to 100 pg/mL on a consistent patch or gel regimen, though some women feel well at lower values. Progesterone: In a natural luteal phase, serum progesterone rises to about 5 to 20 ng/mL. For endometrial protection in women with a uterus taking systemic estrogen, micronized progesterone is typically given cyclically or continuously. I do not chase a serum “target” on HRT, since oral progesterone undergoes first-pass metabolism and clinical response, bleeding patterns, and endometrial thickness on ultrasound give better feedback.
Thyroid hormones
- TSH: Most labs cite 0.4 to 4.0 mIU/L. On levothyroxine, many patients feel best with TSH between about 0.5 and 2.5 mIU/L, provided there is no atrial fibrillation or bone risk. For central hypothyroidism, TSH misleads and free T4 guides therapy. Free T4 and free T3: Typical free T4 ranges around 0.8 to 1.8 ng/dL, and free T3 around 2.3 to 4.2 pg/mL. On levothyroxine, I aim free T4 in the mid to upper normal range, allow T3 to sit where it lands, and judge by symptoms and heart rhythm. Combination therapy can help a subset, but I use it thoughtfully due to variability and the risk of overtreatment.
Cortisol
- Morning serum cortisol at 8 to 9 a.m. often falls around 10 to 20 mcg/dL, with very low values prompting evaluation for adrenal insufficiency. Late-night salivary cortisol should be low; persistent elevation points toward Cushing physiology. I avoid “adrenal support” steroids unless there is clear deficiency, confirmed by ACTH stimulation testing when needed. Excess glucocorticoids worsen glucose, bone, and mood.
DHEA-S
- DHEA sulfate declines with age; normal bands are age and sex specific. When I use DHEA therapy, I titrate to the upper half of the age-adjusted reference range, then reassess mood, energy, and androgenic side effects such as acne and hair shedding.
Growth hormone and IGF-1
- IGF-1 serves as a stable marker for growth hormone status and is age adjusted. Replacement for adult GH deficiency aims to raise IGF-1 into the mid-normal range for age, avoiding values above the upper limit. I raise doses slowly to avoid edema, arthralgia, and glucose intolerance.
Prolactin and SHBG
- Prolactin should be low to normal unless there is pregnancy or lactation. Elevated levels can depress gonadal hormones and libido. SHBG fluctuates with thyroid status, insulin resistance, and estrogen exposure. I track SHBG because it changes free hormone fractions and can explain discordance between total and free values.
Delivery options and how they steer outcomes
Choosing a delivery method is as important as picking a dose. The route changes risk, peaks and troughs, adherence, and what the lab numbers mean. Oral estrogen increases liver production of clotting factors, so I favor transdermal estrogen for women with migraine, obesity, or clot risk. Testosterone injections give precise dosing and fast adjustments, but the peaks cause mood swings and erythrocytosis in some men. Pellets offer convenience but are hard to fine tune and can sit high for months.
Below is a compact comparison of common delivery methods and what I weigh in practice.
- Transdermal estrogen patch or gel: steady levels, lower venous clot risk than oral, useful in migraine and metabolic syndrome. Skin reactions occur in a minority, and patches can fall off with sweat or swim. Oral estradiol: simple and inexpensive, but higher clot and stroke risk in susceptible patients due to hepatic first-pass effects. I prefer the lowest effective dose. Micronized progesterone oral: sedating benefit at night, favorable lipid effects compared with some synthetics. Not ideal for those who feel groggy in the morning. Testosterone injections: flexible dosing, rapid titration, inexpensive. Peaks and troughs can drive mood and hematocrit changes if intervals stretch too long. Testosterone transdermal (gel or cream): more physiologic daily rhythm, easier on hematocrit. Risk of skin transfer to partners or children, and variable absorption in high SHBG states.
Safety, trade-offs, and the role of bioidentical and compounded options
Bioidentical hormones, best hormone therapy New Providence NJ like estradiol and micronized progesterone, match human molecules. In most cases, I prefer them. The term has been co-opted, though, and does not always mean safer. FDA-approved bioidentical products have consistent dosing and quality control. Compounded bioidentical hormones may be helpful for custom doses or allergies to excipients, but they vary in potency batch to batch. When I use compounded cream, I verify symptom response against serum or salivary estradiol or progesterone only if it changes clinical decisions, and I counsel on the limits of those measurements.
Pellet hormone therapy can stabilize levels over months, which appeals to travelers and those who forget daily dosing. The flipside is a lack of an “off switch” if hematocrit spikes, acne flares, or mood shifts appear. I reserve pellets for individuals who have already found their sweet spot on injections or transdermals, understand the risks, and have stable labs.
Oral synthetic progestins differ. Medroxyprogesterone acetate, for example, has different vascular and breast effects than micronized progesterone. For women with a uterus on estrogen therapy, I lean toward micronized progesterone unless there is a clear reason to use an alternative.
Special populations and tailored targets
Perimenopause and postmenopause
Perimenopause is turbulent. Ovulation becomes inconsistent, estradiol can spike, then crash, and progesterone is often low. I start with the dominant symptom: night sweats, heavy bleeding, migraines, mood swings. Transdermal low-dose estradiol paired with cyclic or nightly micronized progesterone helps many, and I do not chase estradiol numbers aggressively. In postmenopause, the goal is steadiness. Transdermal estradiol at a dose that restores sleep and stops hot flashes, with endometrial protection, is often enough. Timing matters for cardiovascular risk. Starting hormone therapy within 10 years of the final menstrual period and before about age 60 appears to carry lower risk than starting later, assuming no contraindications like prior stroke or active breast cancer.
Men with low testosterone
Before writing a prescription, I look for reversible drivers: sleep apnea, excess alcohol, opioids, obesity, hypothyroidism, hemochromatosis, depression. If two morning total testosterone levels are low and symptoms match, and reversible causes are handled, I discuss testosterone therapy. Mid-normal troughs reduce side effects. I watch hematocrit every 3 to 6 months in the first year, then at least annually, and pause therapy if it reaches 54 percent or higher. Baseline PSA and digital rectal exam are prudent for men over 40 to 50 depending on risk. Libido often improves within weeks, mood and body composition over months, and bone density over a longer horizon. I warn men who want children that exogenous testosterone suppresses sperm production. If fertility is a goal, we often use clomiphene or hCG instead.
Gender-affirming hormone therapy
For transfeminine care, typical estradiol targets are roughly 100 to 200 pg/mL, with total testosterone suppressed to below about 50 ng/dL. I favor transdermal estrogen in those with clot risk factors and consider adding spironolactone or GnRH analogs for androgen suppression. For transmasculine care, total testosterone in the mid-normal male range, often 400 to 700 ng/dL measured midway between injections or as a trough depending on schedule, supports virilization. Hematocrit, lipids, liver enzymes, and mental health deserve routine monitoring. These ranges aim for physiologic puberty and maintenance, not bodybuilding peaks.
Thyroid autoimmunity
" width="560" height="315" style="border: none;" allowfullscreen="" > Hashimoto thyroiditis can leave people with fluctuating needs. I dose to steady symptoms with TSH near 1 to 2 mIU/L and free T4 mid to high normal, watching for atrial fibrillation risk as age advances. Selenium deficiency, iron deficiency, and celiac disease can worsen symptoms and can be checked when the picture does not add up. I do not escalate levothyroxine to chase a low-normal TSH if the patient feels well with a higher value and the free hormones are normal.
Athletes and highly active adults
High training loads lower reproductive hormones and alter SHBG. Before starting hormone optimization, I address energy availability, protein intake, and sleep. Chasing testosterone into the upper end of normal while the athlete is under-fueled invites injury, mood swings, and inconsistent performance. I have seen symptoms resolve with 300 to 500 additional daily calories and a 2 to 3 week reduction in training intensity without any hormone prescription.
A few clinical vignettes
A 51-year-old executive had night sweats, sleep disruption, and a rising LDL. She feared estrogen due to a relative with breast cancer. We reviewed her personal risk, which was average. We started a 50 mcg transdermal estradiol patch with 100 mg micronized progesterone nightly. Her hot flashes stopped within two weeks, sleep stabilized, and her LDL improved with concurrent diet changes. Serum estradiol was 58 pg/mL, but we did not adjust based on the number alone. She stayed at that dose for two years with normal mammograms and a thin endometrium on ultrasound.
A 44-year-old firefighter had low libido and fatigue. Two morning total testosterone values were 280 and 295 ng/dL, SHBG 18 nmol/L, hematocrit 47 percent, and untreated sleep apnea. We prioritized CPAP and lost 18 pounds over four months. His total testosterone rose to 380 ng/dL, free testosterone moved into the middle of normal, and symptoms improved enough that he deferred TRT. He decided against medication because his goals were met without it.
A 60-year-old trans woman on oral estradiol had leg swelling and a family history of venous clots. We switched her to transdermal estradiol and adjusted the dose to keep estradiol near 130 pg/mL with testosterone suppressed. The edema resolved, and she maintained breast development and mood stability.
Getting the lab work right
Small errors in testing create big detours in care. I give patients a short checklist so the numbers we act on match reality.
- Standardize timing: morning cortisol at 8 to 9 a.m.; thyroid labs at least six weeks after a dose change; testosterone levels at trough for weekly injections or midway for twice-weekly; estradiol at a consistent interval from the last dose when used to assess a regimen. Use the right assays: LC-MS/MS for low testosterone in women and men with borderline results; sensitive estradiol assays in men and postmenopausal women. Control variables: avoid heavy exercise and biotin supplements for 24 to 48 hours before thyroid testing; fast for lipid panels that guide risk around HRT or TRT decisions. Bring context: record dose timing, route, and any missed doses in the week before the draw. Recheck after changes: wait long enough for steady state, then reassess symptoms two to four weeks after labs to see if numbers translate into better days.
When not to chase numbers
Not every complaint is a hormone problem, and not every number worth measuring is worth normalizing. I have seen free testosterone pushed higher to fix fatigue that was really depression, estradiol raised to quiet hot flashes caused by nightly wine, and thyroid combinations piled on to chase T3 for brain fog rooted in apnea. If a dose increase does not match a symptom curve, pause and reassess. Good hormone treatment feels like alignment, not like force.
For women on menopause therapy, targeting a specific estradiol level is less important than finding the lowest dose that controls vasomotor symptoms and preserves sleep and bone without side effects. For men on TRT, a total testosterone of 650 ng/dL with stable energy, normal hematocrit, and good mood is better than 900 ng/dL with irritability and thick blood. For transgender patients, stable values in target ranges matter, but the goals are social and functional congruence, not a trophy lab report.
Monitoring and course corrections
Start with a baseline that includes a full blood count, metabolic panel, lipids, HbA1c if indicated, PSA in appropriate men, and relevant hormones. Early in therapy, check more often, then lengthen intervals. For TRT, I retest at 6 to 8 weeks to catch hematocrit trends. For menopause hormone therapy, once symptoms stabilize and no side effects appear, annual checks are often enough, with mammography and bone density per guidelines. For thyroid therapy, I test 6 weeks after dose changes and semiannually once stable. For GAHT, I check levels every 3 months in the first year, then 6 to 12 months when stable, while monitoring potassium with spironolactone, hematocrit with testosterone, and liver enzymes with certain anti-androgens.
Adjustments should be small and spaced out. Halving or doubling a dose invites overshoot and frustration. If a number and a symptom disagree, verify timing, check adherence, and revisit the delivery method before changing the milligrams.
Interacting conditions and medications
Many non-hormonal factors pull the strings. SSRIs can blunt libido, statins can nudge glucose, antipsychotics can raise prolactin. Thyroid hormone needs can rise in pregnancy, drop with aging, and shift with weight changes. Metformin can lower testosterone in some women with PCOS by improving insulin sensitivity, which then decreases ovarian androgen production. Glucocorticoids flatten testosterone and growth hormone. Always map the medication list and the health timeline before attributing a symptom to a low hormone.
Practical notes on hormone clinics and specialists
Choosing a hormone doctor is like picking a mountain guide. Look for thoughtful risk discussion, not just salesmanship. Be wary of promises of anti-aging hormone therapy that ignores your family history and current medications. A solid hormone clinic will ask about sleep, stress, nutrition, and movement before offering prescriptions. It will explain the difference between FDA-approved bioidentical hormone replacement therapy and compounded options, including cost, consistency, and oversight. It will talk plainly about fertility, sexual function, cancer screening, and mental health as part of care.
The bottom line on targets and personalization
Good hormone levels treatment marries physiology and lived experience. The targets give structure:
- Testosterone in men commonly 400 to 700 ng/dL as a trough goal on weekly injections, with free testosterone in the mid to upper reference range if symptoms guide it and hematocrit stays below 54 percent. Estradiol in menopause therapy sufficient to stop hot flashes and restore sleep, often achieved with transdermal delivery that yields around 50 to 100 pg/mL, with progesterone added for endometrial protection if there is a uterus. TSH near 0.5 to 2.5 mIU/L on levothyroxine for many, with free T4 mid to upper normal, and careful attention to heart and bone. IGF-1 in the mid-normal range for age if growth hormone deficiency is treated, avoiding edema and glucose problems. For gender-affirming hormone therapy, estradiol near 100 to 200 pg/mL with suppressed testosterone for transfeminine care, and mid-normal male testosterone for transmasculine care with close hematocrit monitoring.
Personalized goals refine those targets based on age, risks, symptoms, and preferences. Hormone balancing is not about perfection on paper. It is about better mornings, steadier energy, restored relationships, and lower long-term risk, achieved with careful dosing, the right delivery method, and thoughtful follow-up. When numbers and narratives agree, hormone optimization stops being a marketing phrase and becomes real hormone health treatment.